CAJ | 학술논문

目的：观察细胞因子诱导的杀伤细胞（CIK细胞）对造血干细胞移植后血液肿瘤患者维持治疗的疗效。方法2005年9月至2010年6月收治血液恶性肿瘤患者12例，其中行自体造血干细胞移植8例，异基因造血干细胞移植4例；移植造血重建后1~3个月内，利用血细胞分离机分离患者（自体移植）及供者（异体移植）的外周血单个核细胞，在体外用多种细胞因子[抗CD3单克隆抗体（OKT3）、白介素-2（IL-2）、干扰素-γ（IFN-γ）等）]共同培养后获得CIK细胞，分次回输给患者。随访观察患者接受治疗后血常规及骨髓等指标的变化及不良反应，同时记录患者的生存期。结果8例自体干细胞移植患者有2例复发，其中1例17个月后死亡，其余6例长期生存；4例异体干细胞移植患者有1例复发，5个月后死亡，其余3例长期生存；4例患者静脉滴注CIK细胞时出现畏寒、寒战、发热，经对症处理均缓解，其余未见不良反应。结论造血干细胞移植后CIK细胞生物治疗延长了患者的生存期，改善了患者的生活状况，未见明显不良反应。
목적：관찰세포인자유도적살상세포（CIK세포）대조혈간세포이식후혈액종류환자유지치료적료효。방법2005년9월지2010년6월수치혈액악성종류환자12례，기중행자체조혈간세포이식8례，이기인조혈간세포이식4례；이식조혈중건후1~3개월내，이용혈세포분리궤분리환자（자체이식）급공자（이체이식）적외주혈단개핵세포，재체외용다충세포인자[항CD3단극륭항체（OKT3）、백개소-2（IL-2）、간우소-γ（IFN-γ）등）]공동배양후획득CIK세포，분차회수급환자。수방관찰환자접수치료후혈상규급골수등지표적변화급불량반응，동시기록환자적생존기。결과8례자체간세포이식환자유2례복발，기중1례17개월후사망，기여6례장기생존；4례이체간세포이식환자유1례복발，5개월후사망，기여3례장기생존；4례환자정맥적주CIK세포시출현외한、한전、발열，경대증처리균완해，기여미견불량반응。결론조혈간세포이식후CIK세포생물치료연장료환자적생존기，개선료환자적생활상황，미견명현불량반응。
Objective To investigate the effects of the maintenance treatment of adoptive immunotherapy of cytokine in-duced killer(CIK) cells for the patients with malignant hematopathy previously given haemopoietic stem cell transplantation (HSCT). Methods Among the 12 patients with malignant hematopathy ,who were received from September 2005 to June 2010 ,8 patients were treated with auto-hematopoietic stem cell transplantation (auto-HSCT) and 4 with allo-hematopoietic stem cell transplanta-tion (allo-HSCT). It was used the blood cell separator to separate the peripheral blood mononuclear cells of the patients (auto transplantation) and the suppliers(allotransplantation) within 1-3 months after rebuilding of transplantation and blooding. The CIK cells were obtained after cultivating with various cells such as OKT3,IL-2,IFN-γtogether in vitro and retransformed to the patients in times. Follow-up observed the indicators of blood routine examination and bone marrow as well as adverse reaction ,and recorded the patients′lifetime. Results 2 cases relapsed among 8 patients with auto-HSCT including 1 died 17 months after the treatment,and the other 6 cases had long-term survival;1 case recurred among 4 patients with allo-HSCT,and died after 5 months,the other 3 cases had long-term survival. In the process of CIK for intravenous injection,4 cases had chills,shiver,fever, and got alleviated after symptomatic treatment ,there were no adverse reaction on the others. Conclusion CIK biological therapy after haemopoietic stem cells transplantation extended the survival time of the patients ,improved their life condition without obvi-ous adverse reaction.